These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35284802)

  • 41. Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review.
    Farooqui AA; Ashraf A; Farooq TB; Anjum A; Rehman SU; Akbar A; Kanate A; Dean R; Ahmed MQ; Tariq MJ; Nabeel S; Faisal MS; Anwer F
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e414-e426. PubMed ID: 32291235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
    Seiter K; Mamorska-Dyga A
    Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.
    Kutsch N; Holmes EE; Robrecht S; Schüler G; Vehling-Kaiser U; Decker T; Müller-Hagen S; Heinisch K; Böttcher S; Ritgen M; Kreuzer KA; Stilgenbauer S; Fink AM; Fischer K; Eichhorst B; Hallek M; Wendtner CM
    Leuk Lymphoma; 2023 Feb; 64(2):478-482. PubMed ID: 36423347
    [No Abstract]   [Full Text] [Related]  

  • 44. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
    Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S
    J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL.
    Mascolo A; Di Napoli R; Balzano N; D'Alessio E; Izzo I; Rossi F; Paolisso G; Capuano A; Sportiello L
    Front Pharmacol; 2023; 14():1229304. PubMed ID: 37654615
    [No Abstract]   [Full Text] [Related]  

  • 46. Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
    Moreno-Martínez E; De la Serna-Torroba J; Escudero-Vilaplana V; Hernández-Rivas JÁ; Sánchez-Cuervo M; Sánchez-Hernández R
    Farm Hosp; 2022 Apr; 46(3):121-132. PubMed ID: 36183205
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Therapeutic Options for "Slow go" Patients with Chronic Lymphocytic Leukemia].
    Smolej L
    Klin Onkol; 2015; 28 Suppl 3():3S30-8. PubMed ID: 26489499
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia.
    Davids MS; Telford C; Abhyankar S; Waweru C; Ringshausen I
    Leuk Lymphoma; 2021 Oct; 62(10):2342-2351. PubMed ID: 33955326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma.
    Tam CS; Quach H; Nicol A; Badoux X; Rose H; Prince HM; Leahy MF; Eek R; Wickham N; Patil SS; Huang J; Prathikanti R; Cohen A; Elstrom R; Reed W; Schneider J; Flinn IW
    Blood Adv; 2020 Oct; 4(19):4802-4811. PubMed ID: 33022066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Ryan CE; Davids MS; Hermann R; Shahkarami M; Biondo J; Abhyankar S; Alhasani H; Sharman JP; Mato AR; Roeker LE
    Future Oncol; 2022 Oct; 18(33):3689-3699. PubMed ID: 36102212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia.
    Pejsa V; Lucijanic M; Vrkljan Vuk A; Stoos-Veic T; Jaksic O; Jonjic Z; Pirsic M; Prka Z; Ivic M; Fazlic Dzankic A; Mitrovic Z
    Leuk Lymphoma; 2020 Apr; 61(4):934-939. PubMed ID: 31842643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
    Shah A
    Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination therapy with the type II anti-CD20 antibody obinutuzumab.
    Klein C; Bacac M; Umana P; Fingerle-Rowson G
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical application of obinutuzumab for treating chronic lymphocytic leukemia.
    Luan C; Chen B
    Drug Des Devel Ther; 2019; 13():2899-2909. PubMed ID: 31692500
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia.
    Bourrier N; Landego I; Bucher O; Squires M; Streu E; Hibbert I; Whiteside T; Gibson SB; Geirnaert M; Johnston JB; Dawe DE; Banerji V
    BMC Cancer; 2022 Feb; 22(1):148. PubMed ID: 35123433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia.
    Sachdeva M; Dhingra S
    Int J Appl Basic Med Res; 2015; 5(1):54-7. PubMed ID: 25664270
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
    Morabito F; Gentile M; Seymour JF; Polliack A
    Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
    Samineni D; Gibiansky L; Wang B; Vadhavkar S; Rajwanshi R; Tandon M; Sinha A; Al-Sawaf O; Fischer K; Hallek M; Salem AH; Li C; Miles D
    Adv Ther; 2022 Aug; 39(8):3635-3653. PubMed ID: 35708885
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL.
    Gibiansky E; Gibiansky L; Carlile DJ; Jamois C; Buchheit V; Frey N
    CPT Pharmacometrics Syst Pharmacol; 2014 Oct; 3(10):e144. PubMed ID: 25353187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.